Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

  • STATUS
    Recruiting
  • End date
    Mar 31, 2025
  • participants needed
    44
  • sponsor
    M.D. Anderson Cancer Center
Updated on 16 May 2021
cancer
stem cell transplantation
graft versus host disease
lymphoid leukemia
fludarabine
tacrolimus
hla-a
lymphoma
bone marrow transplant
methotrexate
rituximab
filgrastim
carbon monoxide
ejection fraction
monoclonal antibodies
melphalan
cell transplantation
leukemia
bone marrow procedure
antithymocyte globulin
b-cell acute lymphoblastic leukemia
human chorionic gonadotropin
chemotherapy drug
monoclonal antibody therapy
chemotherapy regimen
allogeneic bone marrow transplantation
antibody therapy
inotuzumab
b acute lymphoblastic leukemia

Summary

The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn if inotuzumab ozogamicin when given after a stem cell transplant can help control leukemia and lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-positive cancer cells in a targeted way and delivers ozogamicin to kill them. Giving chemotherapy before a bone marrow or peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Sometimes the transplanted cells from a donor attack the body's normal cells (called graft-versus-host disease). Giving tacrolimus and filgrastim before or after the transplant may stop this from happening. Fludarabine, bendamustine, melphalan, and rituximab are commonly given before stem cell transplants. Giving inotuzumab ozogamicin with chemotherapy may work better in treating patients with leukemia or lymphoma undergoing stem cell transplantation.

Description

PRIMARY OBJECTIVE:

I. To assess the safety of the addition of inotuzumab ozogamicin (IO) pre- and post-allogeneic transplantation in patients with CD22-positive hematological malignancies.

SECONDARY OBJECTIVES:

I. Overall survival, progression-free survival and relapse rates. II. Treatment-related mortality. III. Cumulative incidence of acute and chronic graft-versus-host disease (GVHD).

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients with acute lymphoblastic leukemia (ALL) receive inotuzumab ozogamicin intravenously (IV) over 1 hour on day -13, fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on day -2, and tacrolimus IV continuously beginning on day -2 then orally (PO) once daily (QD) or twice daily (BID) for about 6 months. Patients receiving stem cells from a matched unrelated donor (MUD), receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1 and not receive chemotherapy drugs. Patients also receive bone marrow or peripheral blood progenitor cells IV on day 0. Patients then receive methotrexate IV over 30 minutes on days 1, 3, 6, and 11 and filgrastim-sndz subcutaneously (SC) QD beginning 1 week after the transplant until blood cell levels return to normal. Patients with CD22-positive cancer, receive rituximab IV over 4-6 hours on days 1 and 8.

GROUP II: Patients with lymphoma receive inotuzumab ozogamicin IV over 1 hour on day -13, fludarabine IV over 1 hour and bendamustine IV over 30 minutes to 1 hour on days -5 to -3, and tacrolimus IV continuously beginning on day -2 then PO QD or BID for about 6 months. Patients receiving stem cells from a MUD, receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1 and not receive chemotherapy drugs. Patients also receive bone marrow or peripheral blood progenitor cells IV on day 0. Patients then receive rituximab IV over 4-6 hours on days 1 and 8, methotrexate IV over 30 minutes on days 1, 3, and 6, and filgrastim-sndz SC once a day beginning 1 week after the transplant. Patients who received a stem cell transplant from a MUD also receive methotrexate IV over 30 minutes on day 11.

MAINTENANCE: Between 45 and 100 days after stem cell transplantation, all patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 2. Beginning 28 to 100 days after start of first cycle, patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 2 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Details
Condition childhood ALL, Lymphoma, Lymphoproliferative Disorder, Lymphoma, Non-Hodgkin's Lymphoma, B Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Lymphocytic Leukemia, Acute, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, CD22 Positive, Lymphoproliferative disorders, Lymphocytic Neoplasm, acute lymphoblastic leukemia, leukemia, acute lymphoblastic, pro b, lymphomas, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all)
Treatment Rituximab, anti-thymocyte globulin, methotrexate, melphalan, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, Fludarabine, Tacrolimus, Bendamustine, Inotuzumab Ozogamicin, Filgrastim-sndz
Clinical Study IdentifierNCT03856216
SponsorM.D. Anderson Cancer Center
Last Modified on16 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Young adults (age 18-35) with ALL will be included only if they are not eligible for myeloablative transplants
CD22+ lymphoid malignancies including B acute lymphoblastic leukemia (B-ALL)
Eligible to receive a reduced-intensity allogeneic hematopoietic stem cell transplantation (alloSCT)
Donor: HLA compatible related or matched unrelated donor (HLA-A, B, C, DRB1)
Performance status of 0 to 2
Creatinine less than or equal to 1.6 mg/dL (at time of study entry)
Bilirubin less than 1.6 mg/dL (at time of study entry)
Serum glutamate pyruvate transaminase (SGPT) < 2 x upper limit of normal (ULN) (at time of study entry)
Ejection fraction >= 40% (at time of study entry)
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% (at time of study entry)
Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post menopausal or surgically sterilized women

Exclusion Criteria

Human immunodeficiency virus (HIV) positive
Philadelphia chromosome (Ph)-positive ALL
Active and uncontrolled disease/infection
Unable or unwilling to sign consent
Current active hepatic or biliary disease (with exception of Gilbert's syndrome)
Active hepatitis B or C
Recent chemotherapy or radiation within 3 weeks of study entry. Exception: ibrutinib and venetoclax are allowed to within 3 days
Prior inotuzumab ozogamicin within 3 weeks of study entry
Peripheral blast count of greater than 10 K/microL
Corrected QT using Fridericia's formula (QTcF) interval > 470 ms
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note